Integrin Research The Martin Humphries Lab

Virus-Free and Live-Cell Visualizing SARS-CoV-2 Cell Entry for Studies of Neutralizing Antibodies and Compound Inhibitors

The continued corona virus illness 2019 (COVID-19) pandemic, brought on by SARS-CoV-2 an infection, has resulted in a whole bunch of hundreds of deaths. Mobile entry of SARS-CoV-2, which is mediated by the viral spike protein and ACE2 receptor, is a necessary goal for the event of vaccines, therapeutic antibodies, and medicines. Utilizing a mammalian cell expression system, a genetically engineered sensor of fluorescent protein (Gamillus)-fused SARS-CoV-2 spike trimer (STG) to probe the viral entry course of is developed.

In ACE2-expressing cells, it’s discovered that the STG probe has glorious efficiency within the live-cell visualization of receptor binding, mobile uptake, and intracellular trafficking of SARS-CoV-2 underneath virus-free situations. The brand new system permits quantitative analyses of the inhibition potentials and detailed affect of COVID-19-convalescent human plasmas, neutralizing antibodies and compounds, offering a flexible software for high-throughput screening and phenotypic characterization of SARS-CoV-2 entry inhibitors. This strategy might also be tailored to develop a viral entry visualization system for different viruses.

The position of therapeutic plasma trade in clinically amyopathic dermatomyositis with MDA-5 antibody: A case report and assessment of the literature

Clinically amyopathic dermatomyositis (CADM) is a uncommon, aggressive variant of dermatomyositis related to interstitial lung illness (ILD) and refractoriness to immunosuppressants. Antibodies towards melanoma differentiation-associated gene 5 (MDA-5) are sometimes present in sufferers with CADM. We report a affected person with superior CADM with ILD and MDA-5 antibodies who failed to enhance with immunosuppressants. We carried out 2 TPE over three days, utilizing 5% albumin as alternative fluid.

Though 5 complete TPE had been deliberate, he was transferred for lung transplant analysis after the second TPE; he died 16 days after switch with out receiving a transplant. A literature assessment recognized 4 sufferers with CADM and MDA-5 antibodies handled with TPE; all skilled symptomatic enchancment of their ILD. We attribute our affected person’s final result to the superior nature of his illness quite than a failure of TPE. Further analysis could point out a attainable reclassification of CADM with MDA-5 antibodies in future ASFA tips.

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Size Protein for Concentrating on Mouse Dendritic Cells In Vitro and In Vivo

Focused antigen supply to cross-presenting dendritic cells (DC) in vivo effectively induces T effector cell responses and shows a beneficial strategy in vaccine design. Antigen is delivered to DC by way of antibodies particular for endocytosis receptors corresponding to DEC-205 that induce uptake, processing, and MHC class I- and II-presentation. Environment friendly and dependable conjugation of the specified antigen to an acceptable antibody is a essential step in DC concentrating on and amongst different components is determined by the format of the antigen. Chemical conjugation of full-length protein to purified antibodies is one attainable technique. Prior to now, we have now efficiently established cross-linking of the mannequin antigen ovalbumin (OVA) and a DEC-205-specific IgG2a antibody (αDEC-205) for in vivo DC concentrating on research in mice.

Step one of the protocol is the purification of the antibody from the supernatant of the NLDC (non-lymphoid dendritic cells)-145 hybridoma by affinity chromatography. The purified antibody is activated for chemical conjugation by sulfo-SMCC (sulfosuccinimidyl 4-[N-maleimidomethyl] cyclohexane-1-carboxylate) whereas on the similar time the sulfhydryl-groups of the OVA protein are uncovered via incubation with TCEP-HCl (tris (2-carboxyethyl) phosphine hydrochloride).

Extra TCEP-HCl and sulfo-SMCC are eliminated and the antigen is combined with the activated antibody for in a single day coupling. The ensuing αDEC-205/OVA conjugate is concentrated and free of unbound OVA. Profitable conjugation of OVA to αDEC-205 is verified by western blot evaluation and enzyme-linked immunosorbent assay (ELISA). We’ve got efficiently used chemically crosslinked αDEC-205/OVA to induce cytotoxic T cell responses within the liver and to check completely different adjuvants for his or her potential in inducing humoral and mobile immunity following in vivo concentrating on of DEC-205⁺ DC.

Past that, such chemically coupled antibody/antigen conjugates provide beneficial instruments for the environment friendly induction of vaccine responses to tumor antigens and have been confirmed to be superior to classical immunization approaches relating to the prevention and remedy of assorted varieties of tumors.

Excessive seroprevalence of anti-Fasciola antibody amongst cattle farm staff and dwellers in Kelantan

Human fascioliasis is a public well being drawback significantly in areas the place ruminants are raised. The goals of this research had been to find out the seroprevalence of anti-Fasciola antibody and the related danger components amongst cattle farm staff and dwellers in Kelantan.

A complete of 90 blood samples had been collected on this cross-sectional research. A set of validated questionnaire was used to acquire data on socio-demographic profiles and dietary habits of members. The sera had been subjected to enzyme linked immunosorbent assay (ELISA) for the detection of anti-Fasciola IgG antibody. The affiliation between seropositivity and the numerous danger components had been decided by way of logistic regression. From the consequence, serological screening revealed 60 (67%) members optimistic for anti-Fasciola IgG antibody.

Mouse Anti-Human VEGF-A
MBS690837-01mg	MyBiosource	0.1mg	EUR 430

Mouse Anti-Human VEGF-A
MBS690837-5x01mg	MyBiosource	5x0.1mg	EUR 1645

Mouse Anti-Human VEGF-A
MBS690997-02mg	MyBiosource	0.2mg	EUR 430

Mouse Anti-Human VEGF-A
MBS690997-5x02mg	MyBiosource	5x0.2mg	EUR 1645

Mouse anti VEGF-A (#3) (human)
101-M59	Angio Proteomie	100ug	EUR 297.6

Mouse anti VEGF-A (#3C5) (human)
101-M56	Angio Proteomie	100ug	EUR 297.6

Mouse anti VEGF-A (#7G7) (human)
101-M58	Angio Proteomie	100ug	EUR 297.6

MOUSE ANTI MOUSE VEGF
MBS219840-01mg	MyBiosource	0.1mg	EUR 965

MOUSE ANTI MOUSE VEGF
MBS219840-5x01mg	MyBiosource	5x0.1mg	EUR 4165

Mouse Monoclonal anti-human VEGF-A 165
hAP-0009	Angio Proteomie	100ug	EUR 250

Mouse Monoclonal anti-human VEGF-A 165
hAP-0009A	Angio Proteomie	100ug	EUR 250

RABBIT ANTI MOUSE VEGF
MBS221280-01mg	MyBiosource	0.1mg	EUR 660

RABBIT ANTI MOUSE VEGF
MBS221280-5x01mg	MyBiosource	5x0.1mg	EUR 2795

Mouse VEGF-A (164)
vAP-0001	Angio Proteomie	1ml	EUR 1620

Recombinant Mouse VEGF-A/VEGF164
CX73-10ug	Novoprotein	10ug	EUR 242.4
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

Recombinant Mouse VEGF-A/VEGF164
CX73-1mg	Novoprotein	1mg	EUR 2983.2
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

Recombinant Mouse VEGF-A/VEGF164
CX73-500ug	Novoprotein	500ug	EUR 1935.6
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

Recombinant Mouse VEGF-A/VEGF164
CX73-50ug	Novoprotein	50ug	EUR 595.2
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

Recombinant Mouse VEGF-A/VEGF164
AP75658	SAB	1mg	EUR 3489

Mouse anti Human VEGF
MBS226248-01mg	MyBiosource	0.1mg	EUR 355

Mouse anti Human VEGF
MBS226248-5x01mg	MyBiosource	5x0.1mg	EUR 1425

Recombinant Mouse VEGF-A
6494	Immunochemistry	5 µg	EUR 194

Recombinant Mouse VEGF-A
MBS258225-0005mg	MyBiosource	0.005mg	EUR 305

Recombinant Mouse VEGF-A
MBS258225-5x0005mg	MyBiosource	5x0.005mg	EUR 1210

Anti-Mouse VEGF-A Antibody
103-M57	ReliaTech	100 µg	EUR 399
Description: Mouse VEGF is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors; fms-like tyrosine kinase (flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Recombinant murine VEGF (isoform 164) is a 39.0 kDa disulfide-linked homodimeric protein consisting of two 164 amino acid polypeptide chains.

Anti-Mouse VEGF-A Antibody
103-M57A	ReliaTech	100 µg	EUR 399
Description: Mouse VEGF is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors; fms-like tyrosine kinase (flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Recombinant murine VEGF (isoform 164) is a 39.0 kDa disulfide-linked homodimeric protein consisting of two 164 amino acid polypeptide chains.

Anti-Mouse VEGF-A Antibody
103-P36	ReliaTech	100 µg	EUR 245.7
Description: Mouse VEGF is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors; fms-like tyrosine kinase (flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Recombinant murine VEGF (isoform 164) is a 39.0 kDa disulfide-linked homodimeric protein consisting of two 164 amino acid polypeptide chains.

Anti-Mouse VEGF-A Antibody
103-PA03	ReliaTech	200 µg	EUR 246.75
Description: Mouse VEGF is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors; fms-like tyrosine kinase (flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Recombinant murine VEGF (isoform 164) is a 39.0 kDa disulfide-linked homodimeric protein consisting of two 164 amino acid polypeptide chains.

Anti-Mouse VEGF-A Antibody
103-PABi03	ReliaTech	50 µg	EUR 157.5
Description: Mouse VEGF is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors; fms-like tyrosine kinase (flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Recombinant murine VEGF (isoform 164) is a 39.0 kDa disulfide-linked homodimeric protein consisting of two 164 amino acid polypeptide chains.

Recombinant Mouse VEGF-A/VEGF164 Protein
PKSM041180-10ug	Elabscience Biotech	10ug	EUR 178
Description: Mouse

Recombinant Mouse VEGF-A/VEGF164 Protein
PKSM041180-50ug	Elabscience Biotech	50ug	EUR 523
Description: Mouse

Recombinant Mouse VEGF-A/VEGF164 Protein
MBS2553648-001mg	MyBiosource	0.01mg	EUR 220

Recombinant Mouse VEGF-A/VEGF164 Protein
MBS2553648-005mg	MyBiosource	0.05mg	EUR 505

Recombinant Mouse VEGF-A/VEGF164 Protein
MBS2553648-5x005mg	MyBiosource	5x0.05mg	EUR 2270

Recombinant Mouse VEGF164/VEGF-A Protein
RP00597	Abclonal	50μg	EUR 85.02

Mouse VEGF-A ELISA (total)
MBS691463-0096mg	MyBiosource	0.096mg	EUR 815

Mouse VEGF-A ELISA (total)
MBS691463-5x0096mg	MyBiosource	5x0.096mg	EUR 3625

mouse anti-human VEGF mAb
E409C31-m100	EnoGene	100μL	EUR 395
Description: Available in various conjugation types.

Mouse Anti-Human VEGF-C
MBS690194-01mg	MyBiosource	0.1mg	EUR 430

Mouse Anti-Human VEGF-C
MBS690194-5x01mg	MyBiosource	5x0.1mg	EUR 1645

Mouse Anti-Human VEGF-C
MBS690604-01mg	MyBiosource	0.1mg	EUR 430

Mouse Anti-Human VEGF-C
MBS690604-5x01mg	MyBiosource	5x0.1mg	EUR 1645

Mouse Anti-Human VEGF-C
MBS692187-005mg	MyBiosource	0.05mg	EUR 430

Mouse Anti-Human VEGF-C
MBS692187-5x005mg	MyBiosource	5x0.05mg	EUR 1645

Mouse Anti-Human VEGF-C
MBS692192-01mg	MyBiosource	0.1mg	EUR 430

Mouse Anti-Human VEGF-C
MBS692192-5x01mg	MyBiosource	5x0.1mg	EUR 1645

Mouse Anti-Human VEGF-C
MBS692197-01mg	MyBiosource	0.1mg	EUR 430

Mouse Anti-Human VEGF-C
MBS692197-5x01mg	MyBiosource	5x0.1mg	EUR 1645

Mouse anti-Human VEGF mAb
MBS8576845-005mg	MyBiosource	0.05mg	EUR 325

Mouse anti-Human VEGF mAb
MBS8576845-01mLAF405L	MyBiosource	0.1mL(AF405L)	EUR 565

Mouse anti-Human VEGF mAb
MBS8576845-01mLAF405S	MyBiosource	0.1mL(AF405S)	EUR 565

Mouse anti-Human VEGF mAb
MBS8576845-01mLAF610	MyBiosource	0.1mL(AF610)	EUR 565

Mouse anti-Human VEGF mAb
MBS8576845-01mLAF635	MyBiosource	0.1mL(AF635)	EUR 565

Monoclonal Mouse Anti Human VEGF
MBS550070-05mg	MyBiosource	0.5mg	EUR 595

Monoclonal Mouse Anti Human VEGF
MBS550070-1mg	MyBiosource	1mg	EUR 915

Mouse VEGF-A Recombinant Protein
R00045-4	BosterBio	5ug/vial	EUR 310.8
Description: VEGF-A is member of the family of vascular endothelial growth factor (VEGF) proteins, which stimulate vasculogenesis and angiogenesis to restore oxygen supply to tissues. VEGF-A is also a vasodilator and increases microvascular permeability and was originally referred to as vascular permeability factor (VPF). Mouse VEGF-A Recombinant Protein is purified vascular endothelial growth factor A produced in yeast.

Mouse Monoclonal anti-human VEGF-165b
hAP-0051	Angio Proteomie	100ug	EUR 250

Active Recombinant Mouse VEGF-A/VEGF164 Protein
RP01060	Abclonal	10 μg	EUR 130

Genorise® Mouse VEGF-A Polyclonal Antibody
GR131035	Genorise Scientific	100 µg	EUR 398

Mouse VEGF Antibody
GWB-Q01182	GenWay Biotech	0.1 mg	Ask for price

Mouse VEGF Antibody
GWB-6FCAC3	GenWay Biotech	0.1 mg	Ask for price

VEGF-A(VEGF/1063) Antibody
BNC811063-100	Biotium	100uL	EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC811063-500	Biotium	500uL	EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC801063-100	Biotium	100uL	EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF680 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC801063-500	Biotium	500uL	EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF680 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC431063-100	Biotium	100uL	EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC431063-500	Biotium	500uL	EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC051063-100	Biotium	100uL	EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC051063-500	Biotium	500uL	EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC551063-100	Biotium	100uL	EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC551063-500	Biotium	500uL	EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC701063-100	Biotium	100uL	EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC701063-500	Biotium	500uL	EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC611063-100	Biotium	100uL	EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC611063-500	Biotium	500uL	EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCP1063-250	Biotium	250uL	EUR 459.6
Description: Primary antibody against VEGF-A(VEGF/1063), PerCP conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCR1063-250	Biotium	250uL	EUR 459.6
Description: Primary antibody against VEGF-A(VEGF/1063), RPE conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCA1063-250	Biotium	250uL	EUR 459.6
Description: Primary antibody against VEGF-A(VEGF/1063), APC conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCH1063-100	Biotium	100uL	EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCH1063-500	Biotium	500uL	EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCAP1063-100	Biotium	100uL	EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCAP1063-500	Biotium	500uL	EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Mouse Monoclonal anti-human VEGF-C
hAP-0006	Angio Proteomie	100ug	EUR 250

Mouse Monoclonal anti-human VEGF-D
hAP-0007	Angio Proteomie	100ug	EUR 250

Mouse Monoclonal anti-human VEGF-D
hAP-0007A	Angio Proteomie	100ug	EUR 250

Mouse Monoclonal anti-Human VEGF Antibody
xAP-0471	Angio Proteomie	100ug	EUR 280

VEGF mouse
JP27102	Demeditec Diagnostics	96	EUR 611

Goat anti Pig VEGF-A
MBS225044-01mg	MyBiosource	0.1mg	EUR 645

Goat anti Pig VEGF-A
MBS225044-5x01mg	MyBiosource	5x0.1mg	EUR 2730

Rat Monoclonal anti-Mouse VEGF-A Antibody
xAP-0835	Angio Proteomie	100ug	EUR 280

Anti-Rat VEGF-A Antibody
104-P15	ReliaTech	100 µg	EUR 245.7
Description: Rat VEGF (or VEGF-A) is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothellial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors; fms-like tyrosine kinase(flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Recombinant rat VEGF (isoform 164) is a 38.5 kDa disulfide-linked homodimeric protein consisting of two 164 amino acid polypeptide chains.

Anti-Human VEGF-A Antibody
101-M57	ReliaTech	100 µg	EUR 399
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors.

Anti-Human VEGF-A Antibody
101-M60	ReliaTech	100 µg	EUR 173.25
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors.

Anti-Human VEGF-A Antibody
101-M855	ReliaTech	100 µg	EUR 399
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors.

Anti-Human VEGF-A Antibody
101-MBi60	ReliaTech	50 µg	EUR 173.25
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors.

Anti-Human VEGF-A Antibody
102-P91	ReliaTech	100 µg	EUR 245.7
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors.

Anti-Human VEGF-A Antibody
102-P91G	ReliaTech	100 µg	EUR 245.7
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors.

Anti-Human VEGF-A Antibody
102-PA02	ReliaTech	200 µg	EUR 147
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. The antibody is against the N-terminus and will recognize all VEGF-A isoforms.

Anti-Human VEGF-A Antibody
MBS4158488-01mg	MyBiosource	0.1mg	EUR 920

Anti-Human VEGF-A Antibody
MBS4158488-5x01mg	MyBiosource	5x0.1mg	EUR 3880

Anti-bovine VEGF-A PAb
GWB-QIUF78	GenWay Biotech	1 kit	Ask for price

The components discovered to be considerably related to seropositivity towards anti-Fasciola IgG antibody had been the age group of 18 years outdated and above with calculated odds ratio of three.2 instances (p=0.032) and the period of farming actions of greater than 5 years with calculated odds ratio of two.6 instances (p=0.036). In conclusion, Fasciola an infection is prevalent amongst cattle farm staff and dwellers in Kelantan.